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Abstract
Objective—Determine sildenafil exposure and hemodynamic effect in children after Fontan
single-ventricle surgery.
Design—Prospective, dose-escalation trial.
Setting—Single-center, pediatric catheterization laboratory.
Patients—9 children post Fontan single-ventricle surgical palliation and undergoing elective
cardiac catheterization: Median (range) age and weight: 5.2 years (2.5–9.4) and 16.3 kg (9.5–
28.1). Five children (55%) were male, and 6/9 (67%) had a systemic right ventricle.
Interventions—Catheterization and echocardiography performed before and immediately after
single-dose intravenous sildenafil (0.25, 0.35, or 0.45 mg/kg over 20 minutes).
Measurements—Peak sildenafil and des-methyl sildenafil concentration, change in
hemodynamic parameters measured by cardiac catheterization and echocardiography.
Main Results—Maximum sildenafil concentrations ranged from 124–646 ng/ml and were above
the in vitro threshold needed for 77% phosphodiesterase type-5 (PDE-5) inhibition in 8/9 children
and 90% inhibition in 7/7 of children with doses ≥0.35 mg/kg. Sildenafil improved stroke volume
(+22%, p=0.05) and cardiac output (+10%, p=0.01) with no significant change in heart rate in 8/9
children. Sildenafil also lowered systemic (-16%, p=0.01) and pulmonary vascular resistance
index (PVRI) in all 9 children (median baseline PVRI 2.4 [range: 1.3, 3.7]; decreased to 1.9 [0.8,
2.7] WU x m2; p=0.01) with no dose-response effect. Pulmonary arterial pressures decreased
(−10%, p=0.02) and pulmonary blood flow increased (9%, p=0.02). There was no change in
myocardial performance index and no adverse events.
Conclusions—After Fontan surgery, sildenafil infusion acutely improves cardiopulmonary
hemodynamics, increasing cardiac index. For the range of doses studied, exposure was within the
acute safety range reported in adult subjects.
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INTRODUCTION
Staged surgical palliation, culminating in the Fontan procedure, has markedly improved
outcomes for children with single-ventricle heart defects.1 Despite success of this surgical
strategy, circulatory physiology remains abnormal and results in an ongoing mortality risk
and significant long-term morbidities.2–56 In this unique circulation, the two principal
determinants of long-term outcome are low pulmonary vascular resistance (PVR) and
adequate single-ventricle myocardial function.2,5–7 Drugs that lower PVR and/or improve
myocardial performance could optimize circulatory efficiency and potentially improve
outcomes.
Sildenafil is a selective phosphodiesterase type-5 (PDE-5) inhibitor that increases cyclic
guanosine monophosphate and produces vascular smooth muscle relaxation.8 PDE-5 is
highly expressed in the pulmonary vasculature, and sildenafil lowers PVR in adults with
pulmonary arterial hypertension.9 Although not normally expressed in the myocardium,
PDE-5 is up-regulated in states of chronic cardiomyopathy, and PDE-5 inhibition improves
systolic and diastolic performance in both animal models and adults with
cardiomyopathy.10,11 Clinicians have extrapolated these effects to the single-ventricle
population, leading to much enthusiasm for its use within the field.12–14 However, there are
limited data in these patients to support this enthusiasm. Studies to date have focused on
exercise performance in older single-ventricle patients with conflicting results. No studies
have evaluated the acute hemodynamic effect of PDE-5 inhibition after single-ventricle
palliation, particularly in younger patients. Furthermore, no studies have evaluated sildenafil
exposure in these patients where chronic hepatic congestion may alter drug metabolism.
The aim of the present study was to determine intravenous (IV), single-dose sildenafil
pharmacokinetic and hemodynamic effect in children with single-ventricle heart defects. We
previously reported improved PVR but little effect on systemic hemodynamics in patients
after stage II surgery (in press, Pediatric Critical Care Medicine). In this analysis, we focus
on those children who have completed Fontan (stage III) surgical palliation. We
hypothesized that sildenafil would acutely improve cardiopulmonary hemodynamics by
lowering PVR and improving global myocardial performance and that improvements in
cardiopulmonary hemodynamics would be related to drug exposure.
MATERIALS AND METHODS
The study was an open-label, prospective, dose-escalation trial. The institutional review
board of Duke University Medical Center (Durham, North Carolina) approved the study
protocol. Children ≥6 months and ≤10 years of age with single-ventricle heart defects post
Fontan surgical palliation and undergoing cardiac catheterization as a part of their routine
clinical care were eligible for participation. Written informed consent was obtained for all
study participants. Exclusion criteria included: 1) history of serious side effects to prior
sildenafil therapy; 2) history of sildenafil exposure 96 hours prior to the study; 3) pulmonary
venous obstruction; 4) known or suspected pulmonary arterial or cavopulmonary
anastomosis obstruction (catheterization gradient ≥1 mm Hg); 5) known or suspected
coarctation of the aorta (catheterization gradient ≥10 mm Hg); 6) current treatment with
nitrates or alpha blockade medications; and 7) significant renal failure (serum creatinine >2
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times higher than the upper limit of normal), thrombocytopenia (platelet count <50,000 x
106/L), or leukopenia (white blood cell count <2500 grams/dL). The original planned
enrollment was for 12 children post Fontan surgical palliation. However, during the study,
the U.S. Food and Drug Administration (FDA) released a safety advisory recommending
against sildenafil therapy in children secondary to concerns for long-term safety. Following
this advisory, we stopped enrollment in the present study.
Study protocol
All children were studied under general anesthesia with mechanical ventilation and a
fraction of inspired oxygen of 0.21. A standardized general anesthetic approach was utilized.
Induction was achieved with inhalational anesthetics (sevoflurane, 40% oxygen, 60%
nitrous oxide). After induction, tracheal intubation was facilitated with rocuronium (1 mg/
kg). Anesthesia was maintained with approximately 1 minimum alveolar concentration of
isoflurane in room air, and fentanyl (1mcg/kg) was administered prior to arterial and venous
catheter insertions. The depth of anesthesia and ventilation status were kept stable
throughout the hemodynamic portion of the study. Baseline transthoracic echocardiogram
and hemodynamic cardiac catheterization were performed after induction of anesthesia.
Following the initial collection of hemodynamic data, patients were given a single, pre-
determined dose of IV sildenafil (0.25 mg/kg, 0.35 mg/kg, or 0.45 mg/kg) over 20 minutes.
The initial two patients enrolled in the study were assigned to the lowest dose category.
After reviewing for adverse events at this dosing level, subsequent children were assigned to
progressively higher dosing groups. Immediately after completion of the sildenafil infusion,
the hemodynamic catheterization and transthoracic echocardiograms were repeated.
For echocardiograms, a single sonographer performed all studies using a standard cardiac
ultrasound system (Vivid 7®, GE-Vingmed, Horten, Norway). Images were obtained in the
parasternal long, parasternal short, apical, and suprasternal views. Measurements were
performed to assess: 2D systolic ventricular function (fraction of area change [FAC] for
systemic right ventricles, single-plane modified Simpson’s rule ejection fraction [EF] for
systemic left ventricles), speckle tracking systolic function (strain, strain rate), and global
myocardial performance (myocardial performance index).15,16 Speckle tracking analysis
was performed offline using Vector Velocity Imaging™ (Siemens Medical Solutions,
Mountain View, CA). Two physicians associated with the study independently performed all
interpretations of the echocardiographic data. Inter-rater reliability was evaluated using
Spearman’s correlation coefficient with r2 values of 0.58, 0.76, and 0.92 (p<0.05 for all
measures) for FAC, strain rate, and myocardial performance index, respectively.
Catheterization assessment included measurement of saturations by co-oximetry including
mixed venous, Fontan tunnel, pulmonary arterial, and systemic arterial oxygen saturations,
as well as pressure measurements in the Fontan tunnel, branch pulmonary arteries,
pulmonary capillary wedge pressures, single ventricle, ascending aorta, and descending
aorta. Pressures were obtained in the standard fashion using fluid-filled catheters. Systemic
vascular resistance (SVR) index, PVR, pulmonary blood flow, and cardiac output were
calculated using the Fick method. Oxygen consumption was estimated based on age and
heart rate. Flows and resistances were indexed to body surface area. For repeat calculations,
we used the same estimated oxygen consumption as was used for baseline measurements,
and saturations used for calculations were always sampled from the same locations as those
used at baseline.
Pharmacokinetic sampling and analysis
Plasma sildenafil levels were collected immediately following completion of the infusion
and saline flush (t=20 minutes after initiation of drug infusion). Samples were immediately
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transferred into heparinized polypropylene tubes and centrifuged for 5 minutes at 3500
RPM. Samples were then stored in dry ice and transferred to a −70°C freezer. Sildenafil and
des-methyl sildenafil concentrations were determined using a commercially available assay.
The quantitative analysis was performed by Covance Laboratories Inc. (Madison, WI) using
high-performance liquid chromatography with tandem mass spectrometry. The assay lower
limit of quantitation for sildenafil and des-methyl sildenafil detection was 1 ng/mL. The
inter-day error (CV%) for the assay ranged from 1–3.6% across a range of quality control
concentrations from 3.0–350 ng/mL.
Data analysis
The primary hemodynamic outcome measures were change in indexed PVR and change in
indexed cardiac output. Secondary outcome measures included other hemodynamic
variables, as well as echocardiographic measures and exposure response. Statistical analysis
included all patients receiving sildenafil. Demographic data were summarized using
descriptive statistics expressed as median (range). Change in clinical parameters was
expressed as median percent change. Hemodynamic and echocardiographic data were
calculated and presented by dosage group. Standard graphing and screening tests were used
to assess for outliers and to determine data distribution. A Wilcoxon rank sum test was used
to compare hemodynamics and echocardiographic measurements at baseline and after
sildenafil administration. Bivariate linear regression was used to examine the correlation
between sildenafil exposure and hemodynamic outcome measures. Statistical analysis was
performed using SPSS v. 19.0 software package. A 2-tailed p value <0.05 was considered
significant.
RESULTS
Between March 2011 and October 2012, 9 children were enrolled. Median (range) age and
weight were 5.2 years (2.5–9.4) and 16.3 kg (9.5–28.1). Five children (55%) were male, and
6 (67%) children had a systemic right ventricle. Table 1 summarizes demographic features
and baseline hemodynamic parameters.
Hemodynamic effect
Sildenafil effect on hemodynamic parameters immediately following completion of the 20-
minute infusion is shown in Table 2. Because of the small numbers in each group, data were
pooled for assessment of hemodynamic parameters. Sildenafil lowered pulmonary artery
(PA) pressures (−10%, p=0.02), trans-pulmonary gradient (−20%, p=0.01), and indexed
PVR (−44%, p=0.01). Pulmonary blood flow increased (9%, p=0.02) and ventilation
improved (CO2 decreased 5%, p=0.04) (Figure 1). Sildenafil affected systemic
hemodynamics by lowering diastolic blood pressure (−10%, p=0.01) and SVR (−16%,
p=0.01) but had no effect on systolic or mean blood pressure. Stroke volume increased
(+22%, p=0.05) in 8/9 children, resulting in improved cardiac index (+10%, p=0.01) (Figure
2). There was no overall effect on heart rate (p=0.5).
Sildenafil did not affect echocardiographic measures of systolic function (FAC/EF, strain
rate) or global myocardial performance (myocardial performance index). Sildenafil infusion
was well tolerated by all 9 children with no adverse events.
Drug exposure data and effect on hemodynamic response
Sildenafil exposure data are summarized in Figure 3. Sildenafil levels peaked immediately
after infusion completion, with peak levels ranging from 124–646 ng/mL. Peak drug
concentrations were above the in vitro threshold needed for 77% PDE-5 inhibition in 8/9 of
children and 90% inhibition in 7/7 of children with doses ≥0.35 mg/kg.17 Peak levels for the
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active metabolite, des-methyl sildenafil, ranged from 9–82 ng/mL and were seen later,
between 26 and 138 minutes after infusion completion. There was high inter-individual
variability (coefficient of variation = 34% for peak sildenafil levels). Linear regression
analysis demonstrated no association between sildenafil exposure and improvement in
hemodynamic parameters, including PVR (r=0.33, p=0.4), SVR (r=0.02, p=0.98), and
indexed cardiac output (r=0.69, p=0.31).
DISCUSSION
This is the first prospective study evaluating the hemodynamic effect of IV sildenafil in
children with single-ventricle heart defects following Fontan surgical palliation. Sildenafil
lowered systemic and pulmonary vascular resistance and increased pulmonary blood flow as
well as cardiac output. We hypothesize that improved cardiac output was directly related to
pulmonary and/or systemic endothelial modulation as there was no direct effect on
myocardial performance and no change in heart rate.
While studies in animal models and in adult subjects with a variety of cardiomyopathic
conditions demonstrate improved hemodynamics with sildenafil therapy,11,15,18–24 this is
the first prospective study to evaluate hemodynamic effect in children with palliated single-
ventricle heart defects. These patients have unique physiology with passive, non-pulsatile
pulmonary blood flow and a single pumping chamber supporting both the pulmonary and
systemic circulations. Given this physiology, it was previously unclear whether PDE-5
inhibition would have hemodynamic effects similar to those seen in adult patients with right
heart myopathy and/or pulmonary hypertension. These data demonstrate that, despite the
unique pulmonary physiology, PDE-5 inhibition has a similar effect on the pulmonary
vasculature, lowering PA pressures and PVR.
In the absence of a pulmonary pump, low PVR is critically important to the single-ventricle
circulation. While the range of baseline indexed PVR in the current study was not
remarkably abnormal (1.3–3.7 WU x m2), reduction in PVR was seen in all 9 study children
and confirms our prior conclusion from studies after stage II surgery where we demonstrated
that there was no “floor” effect on the capacity of PDE-5 inhibitors to lower PVR.
Importantly, these improvements in pulmonary hemodynamics translate to improved
pulmonary blood flow.
PDE-5 inhibition also acutely increased cardiac output by improving stroke volume. This
effect was seen in 8/9 study children. These data are encouraging as low cardiac output is an
important contributor to short- and long-term morbidity and mortality in this patient
population.6 Strategies to improve cardiac output may have clinical utility in the acute post-
operative period and also over the long term to improve functional status.
From a physiologic standpoint, there are three potential mechanisms that might explain the
noted improvement in cardiac output: 1) improved contractility; 2) increased preload; or 3)
decreased afterload.25 Improved contractility has been demonstrated with PDE-5 inhibition
in animal models of the pressure-loaded and hypertrophied right ventricle.11 Furthermore,
Goldberg at al. previously demonstrated improved myocardial performance index in an
adolescent single-ventricle population with three-week sildenafil therapy.26 However, our
data do not support a direct myocardial effect as there was no improvement in multiple
echocardiographic measures of systolic function, including the myocardial performance
index. Potentially, we did not see a similar effect to that described previously because we
evaluated acute as opposed to chronic ventricular response, or alternatively because the
ventricle is less responsive to PDE-5 inhibition in younger children. It is also possible that
the sample size was too small to detect a small effect on myocardial performance. However,
Tunks et al. Page 5













we did not see an effect in our prior analysis of 12 children post stage II surgery, and, even
when pooling the two cohorts (unpublished data), there was no significant change.
In the absence of improved myocardial contractility, improved cardiac output might result
from improved loading conditions. Preload would be expected to increase with the noted
improved pulmonary blood flow. In addition, cardiac index and stroke volume might be
augmented by decreased afterload (lowered SVR). There may be long-term benefit to
sustained reduced afterload in the single-ventricle population as single-ventricular
dysfunction and atrioventricular valve regurgitation are both important contributors to long-
term failure of surgical palliation strategies. Tempering this enthusiasm, it should be noted
that studies of afterload reduction with angiotensin-converting enzyme inhibitors have
consistently failed to show improvement in important surrogate outcome measures such as
growth or biomarker indices.27
In this small study, sildenafil infusion was acutely well tolerated with no adverse events.
With doses up to 0.45 mg/kg, peak exposure was in the 400–600 ng/mL range, similar to
what we have previously reported in younger single-ventricle patients (in press, Pediatric
Critical Care Medicine) and similar to the range of exposures reported in adults with
standard dosing regimens.28 In general, sildenafil is believed to have a wide acute safety
margin, and exposures up to 1800 ng/mL have been well tolerated in adults.29 However, in a
previous post-operative study in children, bolus IV sildenafil administration was associated
with acute hypotension.30 We did not have any hypotensive events in this cohort with
infusions administered over 20 minutes.
The safety of chronic (3–5-year) sildenafil therapy has recently been questioned after long-
term follow-up of children enrolled in the Sildenafil in Treatment-naive Children, Aged 1–
17 Years, with Pulmonary Arterial Hypertension (STARTS) trial demonstrated an increased
three-year mortality risk in children with idiopathic pulmonary arterial hypertension treated
with high-dose sildenafil when compared to low doses.31 These data resulted in an FDA
safety advisory recommending against sildenafil use in children with pulmonary arterial
hypertension.32 However, this recommendation has been widely debated, and experts in the
pulmonary hypertension field have recently called for further study of sildenafil efficacy and
safety.33 It should also be noted that the European Medicines Agency reviewed the STARTS
data and reached a different conclusion than that of the FDA, deciding that “the data support
the use of sildenafil in children.”34 These conflicting recommendations and opinions
emphasize the importance of population-specific studies, such as the present study, that
evaluate drug exposure and physiologic effects. As our data demonstrate, there is acute
hemodynamic benefit to sildenafil therapy in single-ventricle patients. These pilot data
support further study, potentially in the immediate post-operative period, to determine if the
acute hemodynamic effects of sildenafil are sustained and translate into improved outcomes
for this patient population.
There are several important limitations to the current study. The study was a small, single-
center, open-label study with multiple dosing groups and no control group. This approach
was warranted to optimize safety and because one of the objectives of this study was to
provide pilot data to help justify and optimize design and conduct of future larger scale
clinical trials. By using linear regression to analyze the exposure-response relationship, we
were able to overcome some of the limitations intorduced with mutliple dosing groups in a
small study cohort. However exposure-response is a less clinically meaningful outcome
measure than dose-response. There were also multiple comparisons considering the small
number of patients enrolled, however we identified a priori the primary study end points of
PVR and cardiac output. Furthermore, the changes observed make physiologic sense. For
example, it is logical that lowering of PA pressures might be associated with lowering of
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PVR and trans-pulmonary gradient. In addition, each patient served as his or her own
control, which improves the study power and limits confounding. For example, assumptions
used in hemodynamic calculations (i.e. estimation of oxygen consumption), and the effect of
other hemodynamic factors (i.e. anesthetic agents, mechanical ventilation etc.) are expected
to be constant for baseline and post-sildenafil assessments and therefore would not affect
assessment of subject response to therapy. Sildenafil was the only pulmonary vasodilator
medication administered during this study, so we cannot compare sildenafil effect to that of
selective pulmonary vasodilators such as inhaled nitric oxide or oxygen. Also only acute
response after a single dose was assessed and further study is needed to determine whether
these effects translate to long-term benefit. Although our original study design called for
enrollment of 12 post-Fontan study children, we decided to halt study enrollment and
analyze the data after the FDA safety advisory was issued. Echocardiographic image
acquisition was challenging, as children were stationary and under sterile drapes for the
catheterization procedure. To limit subjectivity of interpretation of the echocardiographic
data, we used two independent physicians to review all study images and perform all
associated measurements.
In conclusion, single-dose IV sildenafil improves systemic and pulmonary hemodynamics
by increasing stroke volume and indexed cardiac output and by lowering indexed PVR, PA
pressure, and trans-pulmonary gradient in a small cohort of children with single-ventricle
heart defects following Fontan surgical palliation. These data are encouraging and provide
proof of concept in support of larger-scale clinical trials to determine if there is sustained
benefit and improvement in clinical end points in this patient population.
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Sildenafil effect on trans-pulmonary gradient, pulmonary blood flow and pulmonary
vascular resistance. WU: Wood Units
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Sildenafil effect on systemic vascular resistance, indexed cardiac output and stroke volume.
WU: Wood Units
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Peak sildenafil and des-methyl sildenafil levels by dosage group. Peak sildenafil levels
predictive of varying degrees of PDE-5 inhibition (from in vitro data) are indicated. PDE-5:
phosphodiesterase type-5.
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Table 2
Sildenafil effect on hemodynamics (n=9)
Baseline median (range) Sildenafil median (range) p
Co-oximetry
CO2 (%) 42 (36,50) 36 (34,48) 0.04
SAO2 (%) 92 (88,98) 94 (90,97) 0.32
Mixed venous saturation (%) 64 (50,76) 70 (60,76) 0.03
Pressures
Fontan pressure (mm Hg) 12 (9,17) 11 (11,15) 0.02
PCWP (mm Hg) 7 (4,11) 7 (4,12) 0.4
Trans-pulmonary gradient (mm Hg) 5 (5,10) 4 (3,9) 0.01
End diastolic pressure (mm Hg) 6 (4,9) 6 (4,9) 0.2
Systolic BP (mm Hg) 79 (64,98) 78 (62,91) 0.1
Diastolic BP (mm Hg) 50 (38,58) 45 (35,55) 0.01
Mean BP (mm Hg) 64 (52,80) 64 (50,68) 0.1
Calculations
Qp (L/min/m2) 2.7 (1.8,3.9) 3.4 (2.2,4.2) 0.02
Qs (L/min/m2) 3.1 (2.0,4.2) 3.4 (2.4,4.4) 0.01
PVRI (WU x m2) 2.4 (1.3,3.7) 1.9 (0.8,2.7) 0.01
SVRI (WU x m2) 17 (13,23) 16 (9,19) 0.01
Echocardiographic assessment
Fractional Area Change 0.36 (0.29, 0.46) 0.40 (0.36, 0.48) 0.2
Strain rate (sec−1) −1.0 (−1.9, −0.6) −1.0 (−1.8, −0.6) 0.7
Myocardial Performance Index 0.56 (0.3, 1.1) 0.61 (0.3,1.2) 0.6
*
SAO2: systemic oxygen saturation, PCWP: pulmonary capillary wedge pressure, Qp: pulmonary blood flow, Qs: systemic blood flow, PVRI:
Pulmonary vascular resistance index, SVRI: Systemic vascular resistance index
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